A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis

Summary

The standard treatment of deep vein thrombosis is given by continuous intravenous infusion of unfractionated heparin. This entails hospitalisation, nursing care, immobility and repeated laboratory tests (e.g. activated partial thromboplastin time [APTT], platelet count). In addition approximately 10% of patients suffer major haemorrhages. The potential advantages of a low molecular weight heparin (CY 216) given subcutaneously were explored in a randomised trial with blind quantitative evaluation of venograms. The study included 166 patients and both “therapeutic efficacy” and “intention to-treat” analyses showed that subcutaneous CY 216 in fixed doses based only on body weight was more effective on the Arnesen and Marder phlebographic scores than continuous i. v. standard heparin with daily dose adjustment according to results of coagulation tests. There was no increase in the risks of pulmonary embolism, haemorrhage or clot extension.

• REFERENCES

• 1 Banssillon V, Dejour H, Besson L. et al Prevention des thromboses veineuses profondes en chirurgie orthopédique pour mise en place d’une prothése totale de hanche. Essai randomisé de détermination de la posologie optimale. Ann Chir 1987. 41 377-385
• 2 Breddin HK, Encke A. Comparison of a low molecular weight heparin and unfractioned heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFA) Group. Br J Surg 1988 75. 1058-1063
• 3 Hirsh H, Levine H. et al. The development of low molecular weight heparin of clinical use. In: Thrombosis & Haemostasis Int Soc Leuven Univ Press; Leuven: 1987: 325-348
• 4 Kakkar VV, Djazaeri B, Fok J. et al. Low molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379
• 5 Kakkar VV, Murray WHJ. Efficacy and safety of low molecular weight heparin (CY 216) in preventing post-operative venous thrombo-embolism: a cooperative study. Br J Surg 1985; 72: 786-791
• 6 Kakkar VV, Murray WHG, Walters HL. et al Treatment of deep vein thrombosis using a low molecular weight heparin (LMWH) (CY 216) - A randomized trial. Thromb Haemostas 1985; 54: 35 (Abstr 203)
• 7 Turpie AGG, Levine MN, Hirsch J. et al A randomized controlled trial of PK 10169 low molecular weight heparin in the prevention of deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 8 Bratt G, Törnebohm E, Granqvist S. et al. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemostas 1985; 54: 813-817
• 1 Faivre R, Maurat JP. et al Le traitement des thromboses veineuses profondes par les héparines. Méd Hyg 1987; 45: 1805-1808
• 10 Holm HA, Ly B, Handeland GF. et al Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractioned and low molecular weight heparin. Haemostasis 16 1986; (Suppl. 02) 30-37
• 11 Janvier G, Winnock S, Dugrais G. et al Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222). Haemostasis 1987; 7: 49-58
• 12 Lockner D, Bratt G, Törnebohm E. et al Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 1986; 16 (Suppl. 02) 25-29
• 13 Parker CJ, Huber DE, Hedges AR, Kakkar VV. A trial of subcutaneous versus intravenous administration of low molecular weight (LMW) heparin and unfractioned (UF) heparin in the treatment of established deep venous thrombosis (DVT). Thromb Haemostas 1987; 58: 380 (Abstr 1390)
• 14 Fareed J, Walenga JM, Hoppenstead D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of Low Molecular Heparins. In: Heparin and Related Polysaccharides Ofosu FA, Danieshefsk YI, Hirsh J. (eds.). Ann NY Acad Sci; 1989. 556 333-353
• 15 Faivre R, Neuhart E, Kiefer Y. et al. Les thrombopenies graves a bas boids moleculaire (CY 216). A propos de 6 observations. Arch Mai Coeur 1985 1. 27-30
• 16 Salzman EW, Deykin D, Shapiro RM. et al Management of heparin therapy: controlled prospective trial. N Engl Med 1975; 292: 1046-1050
• 17 Barritt DW, Jordan SC. et al Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960 1. 1309-1312
• 18 Conrad J, Horellow MH, Samama M. Les traitements des thromboses veineuses profondes par les héparines - Conduite thérapeutique et surveillance biologique. Ann Med Intern 1986; 137 (06) 493-496
• 19 Dalen JE, Hirsh H. American college of chest physicians and the national heart, lung and blood institute - National conference on antithrombotic therapy. Arch Intern Med 1986; 146: 462-472
• 20 Hyers TM. et al. Antithrombotic therapy for venous thromboembolism. Clin Chest Med 1984; 5 (03) 479-486
• 21 Kelton JG, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259-295
• 22 Andersson G, Fagrell B, Holmgren K. et al Subcutaneous administration of heparin - A randomised comparison with intravenous administration of heparin to patients with deep vein thrombosis. Thromb Res 1982; 27: 631-639
• 23 Bentley GP, Vijay V, Kakkar W. et al An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177-187
• 24 Doyle DJ, Turpie AGG, Hirsh J. et al Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-445
• 25 Hirsh J, O’Sullivan EF, Gallus AS. et al Evaluation of subcutaneous calcium heparin therapy in the treatment of thrombo-embolic disease. Med J Australia 1970; 1: 15-16
• 26 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal deep vein thrombosis. Engl J Med 1986; 315 (18) 1109-1114
• 27 Krahenbuhl C, Simon CA, Bouvier CA. et al. Traitement héparini-que. Comparaison entre les voies d’administration intraveinuse et sous-cutanée. Schweiz Med Wschr 1979; 109: 1322-1325
• 28 Walker MG, Shaw JW, Thomson GJL. et al Subcutaneous calcium heparin versus intravenous sodium heparin in the treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. Br Med J 1987; 294
• 29 Lormeau JC, Hajjar R. Méthode de titrage de l’activité anti-facteur Xa du CY 216. Pathol Biol 1988; 36 (04) 335-337
• 30 Arnesen H, Heilo A, Jakobsen E. et al. A prospective study of Streptokinase and Heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978; 203: 457-463
• 31 Marder VJ, Soulen RL, Atchartakarn V. et al. Quantitative veno-graphic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89 (05) 1018-1029
• 32 Murphy ML, Bulloch RT. Factors influencing the restoration of blood flow following pulmonary embolisation as determined by angiography and scanning. Circulation 1968; 38: 1116-1126
• 33 Pitney WR, Pettit JE, Armstrong L. Control of heparin therapy. Br Med J 1970; 2: 139-141
• 34 Sasahara AA, Hull RD, Thomas DP. Treatment of venous thromboembolism. In: Haemostasis and Thrombosis Bloom AL, Thomas DP. (eds). 1987. 47 820-828
• 35 Markwardt F, Klöcking HP. Heparin induced release of plasminogen activator. Special Communication, Haemostasis 1977 6: 370-374
• 36 Reyers I. et al. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 669-674
• 37 Vairel EG. et al. Heparin and a low molecular heparin fraction enhance thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-224